An important point to understand: More screening does not always equal to lives saved
The NY Times talks about a BMJ study suggesting that frequent screenings may be leading to the “increased” melanoma rate. But does it save lives? The answer is no:

Dr. Welch and two colleagues, Dr. Steven Woloshin and Dr. Lisa M. Schwartz, argue that if there was really an epidemic of melanoma – for example, if something in the environment was causing people to get the skin cancer, scientists should see increases in cancers at all stages. This is what happened with lung cancer caused by smoking, and with other cancers caused by toxic substances.

The fact that the increase was seen only in very early stage disease was a tip-off that the epidemic might be less than it seemed, Dr. Welch said.

And that, he says, leads to a difficult question. The point of screening for melanoma is to reduce the death toll from the cancer. But if screening has not altered the number of patients with advanced disease or lowered the death rate, what is its benefit?

The same theory can certainly be applied to PSA and prostate cancer screening.